5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer

被引:0
|
作者
Aditi Patra
Moonmoon Deb
Rajvir Dahiya
Samir Kumar Patra
机构
[1] Bidhan Chandra Krishi Viswaidyalaya,Department of Animal Science
[2] National Institute of Technology,Epigenetics and Cancer Research Laboratory, Department of Life Science
[3] University of California at San Francisco and VA Medical Center,Department of Urology
来源
Clinical Epigenetics | 2011年 / 2卷
关键词
Epigenome; CpG hypermethylation; DNMT; 5-Aza-2′-deoxycytidine; Apoptosis; Prostate cancer;
D O I
暂无
中图分类号
学科分类号
摘要
While studying on epigenetic regulatory mechanisms (DNA methylation at C-5 of –CpG– cytosine and demethylation of methylated DNA) of certain genes (FAS, CLU, E-cadh, CD44, and Cav-1) associated with prostate cancer development and its better management, we noticed that the used in vivo dose of 5-aza-2′-deoxycytidine (5.0 to 10.0 nM, sufficient to inhibit DNA methyltransferase activity in vitro) helped in the transcription of various genes with known (steroid receptors, AR and ER; ER variants, CD44, CDH1, BRCA1, TGFβR1, MMP3, MMP9, and UPA) and unknown (DAZ and Y-chromosome specific) proteins and the respective cells remained healthy in culture. At a moderate dose (20 to 200 nM) of the inhibitor, cells remain growth arrested. Upon subsequent challenge with increased dose (0.5 to 5.0 μM) of the inhibitor, we observed that the cellular morphology was changing and led to death of the cells with progress of time. Analyses of DNA and anti-, pro-, and apoptotic factors of the affected cells revealed that the molecular events that went on are characteristics of programmed cell death (apoptosis).
引用
收藏
页码:339 / 348
页数:9
相关论文
共 50 条
  • [41] Induction of Le(Y) antigen by 5-aza-2'-deoxycytidine in association with differentiation and apoptosis in human pancreatic cancer cells
    Yamada, T
    Ohwada, S
    Saitoh, F
    Adachi, M
    Morishita, Y
    Hozumi, M
    ANTICANCER RESEARCH, 1996, 16 (02) : 735 - 740
  • [42] Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer
    Lemaire, Maryse
    Chabot, Guy G.
    Raynal, Noel J. M.
    Momparler, Louise F.
    Hurtubise, Annie
    Bernstein, Mark L.
    Momparler, Richard L.
    BMC CANCER, 2008, 8 (1)
  • [43] A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer
    Thibault, A
    Figg, WD
    Bergan, RC
    Lush, RM
    Myers, CE
    Tompkins, A
    Reed, E
    Samid, D
    TUMORI, 1998, 84 (01) : 87 - 89
  • [44] Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid
    Yang, H
    Hoshino, K
    Sanchez-Gonzalez, B
    Kantarjian, H
    Garcia-Manero, G
    LEUKEMIA RESEARCH, 2005, 29 (07) : 739 - 748
  • [45] Unconventional genetic determinants of resistance to 5-aza-2′-deoxycytidine.
    Ting, Angela H.
    Matkin, Lars
    CANCER RESEARCH, 2013, 73 (08)
  • [46] Synthesis and properties of oligonucleotides containing 5-aza-2'-deoxycytidine.
    Eritja, R
    Marquez, VE
    Garcia, RG
    NUCLEOSIDES & NUCLEOTIDES, 1997, 16 (7-9): : 1111 - 1114
  • [47] Epigenetic regulation of the circadian clock: role of 5-aza-2′-deoxycytidine
    Tomita, Tatsunosuke
    Kurita, Ryoji
    Onishi, Yoshiaki
    BIOSCIENCE REPORTS, 2017, 37
  • [48] CYTOTOXICITY OF 5-AZA-2'-DEOXYCYTIDINE IN A MAMMALIAN-CELL SYSTEM
    DAVIDSON, S
    CROWTHER, P
    RADLEY, J
    WOODCOCK, D
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) : 362 - 368
  • [49] Phase I trial of continuous infusion 5-aza-2′-deoxycytidine
    Aparicio, A
    Eads, CA
    Leong, LA
    Laird, PW
    Newman, EM
    Synold, TW
    Baker, SD
    Zhao, M
    Weber, JS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (03) : 231 - 239
  • [50] ANTITUMOR EFFECT OF 5-AZA-2'-DEOXYCYTIDINE (5-AZA-DCYD) IN HUMAN HEAD AND NECK (HN) CANCER XENOGRAFTS
    BRAAKHUIS, BJM
    LEYVA, A
    PINEDO, HM
    SNOW, GB
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 299 - 299